REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item: The budget was changed)
Property / budget
 
829,236.6 Euro
Amount829,236.6 Euro
UnitEuro
Property / budget: 829,236.6 Euro / rank
 
Normal rank
Property / EU contribution
 
409,635.99 Euro
Amount409,635.99 Euro
UnitEuro
Property / EU contribution: 409,635.99 Euro / rank
 
Normal rank
Property / co-financing rate
 
49.4 percent
Amount49.4 percent
Unitpercent
Property / co-financing rate: 49.4 percent / rank
 
Normal rank

Revision as of 09:06, 12 February 2022

Project Q2035362 in Italy
Language Label Description Also known as
English
REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT
Project Q2035362 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    409,635.99 Euro
    0 references
    budget
    829,236.6 Euro
    0 references
    co-financing rate
    49.4 percent
    0 references
    start time
    13 December 2016
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
    0 references
    TAKIS SRL
    0 references
    ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
    0 references
    beneficiary
    Q282248
    0 references
    Q277533
    0 references
    Q282249
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
    0 references
    REVER3BAB: A MONOCLONAL ANTIBODY AGAINST THE ERBB3 PROTEIN CAPABLE OF BLOCKING IN VITRO AND IN VIVO CANCER CELLS, WITH POTENTIAL USE AS A THERAPEUTIC AGENT IN CLINICAL USE. (English)
    0 references
    REVER3MAB: UN ANTICORPS MONOCLONAL DIRIGÉ CONTRE LA PROTÉINE ERBB3 QUI PEUT BLOQUER LA PROLIFÉRATION DES CELLULES TUMORALES IN VITRO ET IN VIVO, AVEC UNE UTILISATION POTENTIELLE COMME AGENT THÉRAPEUTIQUE EN CLINIQUE. (French)
    point in time
    16 December 2021
    0 references
    REVER3MAB: EEN MONOKLONAAL ANTILICHAAM GERICHT TEGEN HET ERBB3-EIWIT DAT DE PROLIFERATIE VAN TUMORCELLEN IN VITRO EN IN VIVO KAN BLOKKEREN, MET POTENTIEEL GEBRUIK ALS THERAPEUTISCH MIDDEL IN DE KLINIEK. (Dutch)
    point in time
    23 December 2021
    0 references
    REVER3MAB: EIN MONOKLONALER ANTIKÖRPER, DER GEGEN DAS ERBB3-PROTEIN GERICHTET IST, DER DIE PROLIFERATION VON TUMORZELLEN IN VITRO UND IN VIVO BLOCKIEREN KANN, MIT POTENZIELLER ANWENDUNG ALS THERAPEUTISCHES MITTEL IN DER KLINIK. (German)
    point in time
    24 December 2021
    0 references
    REVER3MAB: ANTICUERPO MONOCLONAL DIRIGIDO CONTRA LA PROTEÍNA ERBB3 QUE PUEDE BLOQUEAR LA PROLIFERACIÓN DE CÉLULAS TUMORALES IN VITRO E IN VIVO, CON POTENCIAL USO COMO AGENTE TERAPÉUTICO EN LA CLÍNICA. (Spanish)
    point in time
    25 January 2022
    0 references
    location (string)
    ROMA
    0 references

    Identifiers

    Italian Unique Project Code
    F87H18000370007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035362&oldid=27872532"